News
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
LOS ANGELES - ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow...
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023. LOS ANGELES - ChromaDex Corp. (NASDAQ:...
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
Tru Niagen® Pro 1,000mg is recommended by physicians and used by pro-athletes as it is clinically proven to boost NAD+ levels by up to 150% in as little as three weeks LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine...
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter,...
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
The global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, ChromaDex, and the #1 selling pet supplement brand in the USA*, Zesty Paws®, debut cellular health supplement featuring ChromaDex's industry leading healthy aging...
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
Celebrating a significant achievement in NAD+ research, these findings contribute to the mounting evidence indicating that NR may serve as a proactive safeguard against inflammatory cytokines in healthy adults and those with inflammation-related disorders LOS ANGELES...
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide...
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. LOS ANGELES - ChromaDex...
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
This partnership positions Tru Niagen for accelerated global expansion given nearly 90% of iHerb sales are outside of the U.S. LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world's...
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
Presentations and live Q&A to take place on Monday, August 14 and Wednesday, August 16 LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be...